-

Phibro Animal Health Corporation Announces Chief Financial Officer Changes

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (the “Company” or “Phibro”) today announced that Richard Johnson, Phibro’s Chief Financial Officer, has informed the Company that he will retire from his position effective November 15, 2020, subsequent to the Company’s annual meeting and completion of the Company’s earnings report for the quarter ending September 30, 2020.

Phibro also announced that Damian Finio will join Phibro on October 26, 2020, and will succeed Mr. Johnson as Phibro’s Chief Financial Officer, effective November 15, 2020. Mr. Johnson will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor.

“I want to take this opportunity to recognize and thank Dick for his many contributions to the success of Phibro over the past 18 years, and to wish him all the best in his retirement,” said Jack Bendheim, Phibro’s Chairman, President and Chief Executive Officer. “I also want to welcome Damian to Phibro. He brings the skills and experience needed to play a key role in Phibro’s future development.”

Since February 2018, Mr. Finio, age 50, has served as Chief Financial Officer of Teligent, Inc. a publicly traded global manufacturer and distributor of topical pharmaceutical products in the United States and injectable pharmaceutical products in Canada. Mr. Finio has over 29 years of financial management experience. From November 2015 through January 2018, Mr. Finio served as Chief Financial Officer of Virtus Pharmaceuticals LLC. Prior to this, Mr. Finio served in a variety of financial roles of increasing responsibility at Daiichi Sankyo Pharma Development, West-Ward Pharmaceuticals (now known as Hikma), and Heritage Pharmaceuticals Inc. (now known as Avet Pharmaceuticals Inc.), after spending nearly fourteen years with AstraZeneca. He began his career in public accounting at KPMG LLP. Mr. Finio has a Bachelor of Science in Accounting from The Pennsylvania State University and a Masters in Business Administration from the University of Delaware, and is an (inactive) Certified Public Accountant and (inactive) Certified Treasury Professional.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a diversified global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For further information, please visit www.pahc.com.

Contacts

Phibro Animal Health Corporation
Richard Johnson
Chief Financial Officer
+1-201-329-7300
Or
investor.relations@pahc.com

Phibro Animal Health Corporation

NASDAQ:PAHC

Release Versions

Contacts

Phibro Animal Health Corporation
Richard Johnson
Chief Financial Officer
+1-201-329-7300
Or
investor.relations@pahc.com

More News From Phibro Animal Health Corporation

Phibro Animal Health Corporation to Participate in Bank of America 2026 Virtual Animal Health Summit

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2026 Virtual Animal Health Summit. Chief Financial Officer, Glenn David; Chief Operating Officer, Larry Miller and Executive Vice President, Corporate Strategy and CEO designate Daniel Bendheim will address financial analysts and investors on Thursday, February 26, 2026, at 10:45 AM ET. The live audio presentation will be available on the Phibro Animal Healt...

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2025, and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended December 31, 2025 (compared to the three months ended December 31, 2024): Net sales of $373.9 million, an increase of $64.6 million, or 21% Net income of $27.5 million, an increase of $24.3 million Dil...

Phibro Animal Health Corporation Declares Quarterly Dividend

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 25, 2026, to stockholders of record at the close of business on March 4, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with liv...
Back to Newsroom